On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries.
In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.
The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.
In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.
Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.
The U.S. Department of Health and Human Services last week cancelled a scheduled meeting of the U.S. Preventive Services Task Force, a 16-member panel that writes guidelines for screening and prevention based on the principles of evidence-based medicine.
Unless you were sleeping under a rock, you are aware of the coordinated attacks on Iran’s nuclear facilities by Israel and the United States.
Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.1,2
